asciminib (Scemblix) Report issue

Small molecule Orphan Drug FDA Approved FDA Fast Track FDA Accelerated Approval FDA Priority Review FDA

Active Ingredient History

NOW
  • Now

Chemistry

  • SMILES: O=C(Nc1ccc(OC(F)(F)Cl)cc1)c1cnc(N2CC[C@@H](O)C2)c(-c2cc[nH]n2)c1
  • InChIKey: VOVZXURTCKPRDQ-CQSZACIVSA-N
  • Mol. Mass: 449.85
  • ALogP: 3.46
  • ChEMBL Molecules:
    asciminib  
    asciminib hydrochloride  
More Chemistry

Pharmacology

Organizations (14)

Research & Development (14)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (1)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (11)

Approved Indications (3)


 

Leukemia, Myelogenous, Chronic, BCR-ABL Positive

Leukemia, Myeloid, Acute (approved 2021)

Philadelphia Chromosome (approved 2021)

Experimental Indications - Clinical Trial Phases 1-4 (9)


 

Biliary Tract Neoplasms (Phase 1/Phase 2)

Hematologic Diseases (Phase 2)

Leukemia, Myelogenous, Chronic, BCR-ABL Positive (Phase 3)

Leukemia, Myeloid (Phase 2)

Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative (Phase 3)

Leukemia, Myeloid, Chronic-Phase (Phase 3)

Leukemia, Myelomonocytic, Chronic (Phase 3)

Neoplasms (Phase 1/Phase 2)

Precursor B-Cell Lymphoblastic Leukemia-Lymphoma (Phase 1)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 17
  • # of Trial Organizations: 14

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue